NUCANA PLC-ADR (NCNA) Stock Overview
NASDAQ:NCNA - US67022C2052 - ADR
NCNA Key Statistics, Chart & Performance
The current stock price of NCNA is 3.36 USD. In the past month the price decreased by -99.83%. In the past year, price decreased by -100%.
NCNA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.68 | 368.08B | ||
| AMGN | AMGEN INC | 13.28 | 155.90B | ||
| GILD | GILEAD SCIENCES INC | 14.83 | 142.38B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.86 | 99.27B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.88 | 62.29B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 59.14B | ||
| ARGX | ARGENX SE - ADR | 76.39 | 43.34B | ||
| ONC | BEONE MEDICINES LTD-ADR | 6.24 | 36.72B | ||
| INSM | INSMED INC | N/A | 27.94B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.19B | ||
| NTRA | NATERA INC | N/A | 22.74B | ||
| BIIB | BIOGEN INC | 8.54 | 20.04B |
Related stock screener links
About NCNA
Company Profile
NuCana Plc is a clinical stage biopharmaceutical company. The firm is focused on developing treatment outcomes for patients with cancer by applying its ProTide technology. The firm's pipeline includes NUC-3373, and NUC-7738. NUC-3373 is a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil (5-FU). 5-FU is a prescribed anti-cancer agent. NUC-3373 has been evaluated in a Phase I clinical trial for patients with advanced solid tumors and is under Phase Ib/II clinical trial for patients with advanced colorectal cancer. NUC-7738 is a ProTide transformation of a nucleoside analog, 3’-deoxyadenosine (3’-Da). The firm is evaluating NUC-7738 in a Phase I/II clinical trial for patients with advanced solid tumors. Its pipeline also includes Acelari, which is a ProTide transformation of the nucleoside analog gemcitabine. The Company’s subsidiaries include NuCana, Inc., NuCana Limited and NuCana BioMed Trustee Company Limited.
Company Info
NUCANA PLC-ADR
Lochside House, 3 Lochside Way
Edinburgh EH12 9DT GB
CEO: Hugh Griffith
Employees: 21
Phone: 4401313571111
NUCANA PLC-ADR / NCNA FAQ
What is the stock price of NUCANA PLC-ADR today?
The current stock price of NCNA is 3.36 USD. The price decreased by -1.18% in the last trading session.
What is the ticker symbol for NUCANA PLC-ADR stock?
The exchange symbol of NUCANA PLC-ADR is NCNA and it is listed on the Nasdaq exchange.
On which exchange is NCNA stock listed?
NCNA stock is listed on the Nasdaq exchange.
What is NUCANA PLC-ADR worth?
NUCANA PLC-ADR (NCNA) has a market capitalization of 1.28B USD. This makes NCNA a Small Cap stock.
How many employees does NUCANA PLC-ADR have?
NUCANA PLC-ADR (NCNA) currently has 21 employees.
Should I buy NUCANA PLC-ADR (NCNA) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of NCNA, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of NCNA, evaluating the profitability, health, valuation and growth aspects
- NUCANA PLC-ADR (NCNA) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- NUCANA PLC-ADR (NCNA) Sales and EPS estimates to see what analysts future expectations are.
- NUCANA PLC-ADR (NCNA) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- NUCANA PLC-ADR (NCNA) Insider and Institutional Ownership to learn about the owners and their transactions.
- NUCANA PLC-ADR (NCNA) Stock Chart to make your own analysis
- NUCANA PLC-ADR (NCNA) Latest news and press-releases to stay up to date.
Does NUCANA PLC-ADR (NCNA) stock pay dividends?
NCNA does not pay a dividend.
When does NUCANA PLC-ADR (NCNA) report earnings?
NUCANA PLC-ADR (NCNA) will report earnings on 2025-11-24, after the market close.
What is the Price/Earnings (PE) ratio of NUCANA PLC-ADR (NCNA)?
NUCANA PLC-ADR (NCNA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.05).
NCNA Technical Analysis
NCNA Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to NCNA. The financial health of NCNA is average, but there are quite some concerns on its profitability.
NCNA Financial Highlights
Over the last trailing twelve months NCNA reported a non-GAAP Earnings per Share(EPS) of -0.05. The EPS decreased by -103.48% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -126.13% | ||
| ROE | -350.55% | ||
| Debt/Equity | 0.02 |